Actuate Therapeutics gets Nasdaq notice for failing minimum bid price rule
Actuate has until April 26, 2027 to lift its stock price back above $1.00 or face possible delisting from the Nasdaq Global Market.
Actuate Therapeutics, Inc. disclosed in an 8-K reporting an event dated October 28, 2026 that it received a written notice from The Nasdaq Stock Market LLC stating that for the last 30 consecutive business days, the bid price for its common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market under Listing Rule 5450(a)(1).1
The notice does not immediately affect trading. Actuate's stock continues to trade on the Nasdaq Global Market under the symbol "ACTU."1 Under Nasdaq Listing Rule 5810(c)(3)(A), the company has an initial compliance period of 180 calendar days, or until April 26, 2027, to regain compliance with the minimum bid price requirement.1
To regain compliance, the closing bid price of Actuate's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period ending April 26, 2027, and the company must otherwise satisfy Nasdaq Global Market listing requirements.1 If it misses that deadline, Actuate may be given a second 180-day period if it applies to transfer its listing to the Nasdaq Capital Market, provided it meets that market's continued listing requirement for market value of publicly held shares and other initial listing standards, aside from the minimum bid price rule, and notifies Nasdaq of its intent to cure the deficiency.1 If compliance is not regained within the allotted periods, including any extensions Nasdaq may grant, the stock will be subject to delisting.1
This is a separate issue from an earlier Nasdaq notice. As previously disclosed in a Form 8-K filed July 17, 2026, Actuate received a notice on July 15, 2026 that it did not comply with the minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(b)(2)(A), with a compliance deadline of January 11, 2027.1 The new bid price notice does not affect the compliance period for that separate market value requirement.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.